Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2020 6
2021 9
2022 15
2023 12
2024 4
2025 9
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID Study.
Fumery M, Caron B, Hébuterne X, Altwegg R, Roblin X, Stefanescu C, Meyer A, Nachury M, Laharie D, Le Berre C, Guillo L, Biron A, Caillo L, Buisson A, Nancey S, Uzzan M, Vuitton L, Gilletta C, Geyl S, Blain A, Kirchgesner J, Ah-Soune P, Duveau N, Vidon M, Abitbol V, Paupard T, Tran-Minh ML, Defrance A, Peyrin-Biroulet L. Fumery M, et al. Among authors: gilletta c. Clin Gastroenterol Hepatol. 2024 Dec;22(12):2451-2458.e1. doi: 10.1016/j.cgh.2024.04.016. Epub 2024 May 9. Clin Gastroenterol Hepatol. 2024. PMID: 38729389
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Danese S, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravata I, Lavie F, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, Gaya DR, Peyrin-Biroulet L; STARDUST study group. Danese S, et al. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):294-306. doi: 10.1016/S2468-1253(21)00474-X. Epub 2022 Feb 1. Lancet Gastroenterol Hepatol. 2022. PMID: 35120656 Clinical Trial.
Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study.
Osty M, Altwegg R, Serrero M, Benezech A, Lecomte A, Cadiot G, Vuitton L, Wampach A, Nancey S, Buisson A, le Berre C, Rouillon C, Gilletta C, Goutorbe F, Fumery M, Hammoudi N, Caillo L, Vidon M, Arab N, Sickersen G, Cavicchi M, Vieujean S, Charkaoui M, Richard N, Wils P, Caron B, Amiot A, Nuzzo A, Laharie D, Kirchgesner J, Uzzan M; GETAID‐J2J group. Osty M, et al. Among authors: gilletta c. Aliment Pharmacol Ther. 2025 Aug;62(4):430-439. doi: 10.1111/apt.70199. Epub 2025 May 22. Aliment Pharmacol Ther. 2025. PMID: 40400411 Free PMC article.
Building a Robust Investigator-Initiated Platform: The I-CARE Experience.
Kirchgesner J, Beaugerie L, Baumann C, Baert F, Rahier JF, Bergemalm D, Cañete F, Caron B, Cossignani M, Dias S, Farkas K, Girod P, Goren I, Holvoet T, Krasz S, Kumar A, Rimmer P, Sheridan J, Thut J, Uzzan M, Viazis N, Weimers P, Zagórowicz E, Buisson A, Avedano L, Rousseau H, Peyrin-Biroulet L, Sebastian S; I‐CARE Collaborator Group. Kirchgesner J, et al. Clin Pharmacol Ther. 2026 Jun;119(6):1537-1546. doi: 10.1002/cpt.70231. Epub 2026 Feb 15. Clin Pharmacol Ther. 2026. PMID: 41693257 Free PMC article.
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
Peyrin-Biroulet L, Rahier JF, Kirchgesner J, Abitbol V, Shaji S, Armuzzi A, Karmiris K, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L; I-CARE Collaborator Group. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2023 Mar;21(3):771-788.e10. doi: 10.1016/j.cgh.2022.09.018. Epub 2022 Sep 22. Clin Gastroenterol Hepatol. 2023. PMID: 36152897 Free article.
Diet and clinical remission in patients with inflammatory bowel disease: A multicenter cross-sectional study.
Fontaine L, Seksik P, Stefanescu C, Nachury M, Nancey S, Savoye G, Allez M, Altwegg R, Laharie D, Serrero M, Franchimont D, Mathieu N, Fumery M, Vuitton L, Nahon S, Gilletta C, Rouillon C, Nuzzo A, Bourreille A, Caron B, Buisson A, Amil M, Charkaoui M, Cadiot G, Caillo L, Simon M, Reenaers C, Hébuterne X, Plastaras L, Atanasiu C, Kwiatek S, Uzzan M, Pelletier AL, Benezech A, Vidon M, Goutorbe F, Geyl S, Cellier C, Montuclard C, Moussata D, Amiot A, Meyer A; GETAID-Diet-in-IBD study group. Fontaine L, et al. Among authors: gilletta c. Dig Liver Dis. 2026 Feb;58(2):220-231. doi: 10.1016/j.dld.2025.12.001. Epub 2025 Dec 30. Dig Liver Dis. 2026. PMID: 41475902 Free article.
A randomized controlled trial of antibiotics targeting adherent and invasive Escherichia coli versus placebo in Crohn's disease: the TEOREM trial.
Carbonnel F, Barnich N, Lepage P, Hébuterne X, Michiels C, Gilletta C, Wils P, Laharie D, Altwegg R, Allez M, Bouhnik Y, Meyer A, Breton C, Agostini H, Molinari D, Sartor RB, Mary JY, Colombel JF, Chevarin C, Faure F, Walter-Petrich A, Chevret S, Buisson A. Carbonnel F, et al. Among authors: gilletta c. J Crohns Colitis. 2025 Jul 3;19(7):jjaf093. doi: 10.1093/ecco-jcc/jjaf093. J Crohns Colitis. 2025. PMID: 40512677 Clinical Trial.
PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission.
Mathieu N, Hupé M, Heluwaert F, Rivière P, Hébuterne X, Chupin A, Abitbol V, Bouguen G, Vuitton L, Gornet JM, Montuclard C, Nancey S, Cadiot G, Wils P, Gilletta C, de Maissin A, Altwegg R, Chanteloup E, Plastaras L, Ah Soune P, Bourreille A, Stefanescu C, Seksik P, Simon M, Uzzan M, Andrau P, Rouillon C, Arondel Y, Buisson A, Peyrin-Biroulet L, Mboup B, Vicaut E, Laharie D. Mathieu N, et al. Among authors: gilletta c. Clin Gastroenterol Hepatol. 2025 Dec;23(13):2597-2606. doi: 10.1016/j.cgh.2025.04.028. Epub 2025 May 19. Clin Gastroenterol Hepatol. 2025. PMID: 40398832 Free article.
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
Louis E, Resche-Rigon M, Laharie D, Satsangi J, Ding N, Siegmund B, D'Haens G, Picon L, Bossuyt P, Vuitton L, Irving P, Viennot S, Lamb CA, Pollok R, Baert F, Nachury M, Fumery M, Gilletta C, Almer S, Ben-Horin S, Bouhnik Y, Colombel JF, Hertervig E; GETAID and the SPARE-Biocycle research group. Louis E, et al. Among authors: gilletta c. Lancet Gastroenterol Hepatol. 2023 Mar;8(3):215-227. doi: 10.1016/S2468-1253(22)00385-5. Epub 2023 Jan 11. Lancet Gastroenterol Hepatol. 2023. PMID: 36640794 Free PMC article. Clinical Trial.
54 results